Key result
Pre-existing immunity to Cas9 variants poses potential challenges for in vivo CRISPR genome editing.
Why the study?
The potential immunogenicity of bacterial Cas9 protein and its impact on persistent in vivo genome editing using CRISPR-Cas9 systems is a significant concern due to pre-existing immunity in some humans and long-term exposure from AAV vector delivery.
Population
Human population with pre-existing immunity to Cas9 variants
Design
Review
Authors
Loading...
Pre-existing Cas9 immunity may warrant screening before in vivo editing; leaves open need for immune-evasive variants or alternatives.
Pre-existing immunity to Cas9 in the human population may pose a significant obstacle to persistent in vivo genome editing.
Gough et al. (2020) conducted a review in Genetic disorders. CRISPR-Cas9 systems was evaluated. In vivo genome editing with CRISPR-Cas9 systems faces potential challenges due to pre-existing immunity to Cas9 variants in a fraction of the human population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: